Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: axial who wrote (12018)	1/26/2003 3:44:08 PM
From: padco	Read Replies (1) \| Respond to of 14101

Jim, I agree completely with the point you are making. You're post reminded me of a remark REK made at the AGM (I believe) where she said that the agencies are always asking for more data. Knowing how expensive and time consuming it is to run a clinical trial, would it not be unreasonable to think they would look at all data collected in a scientific manner. Certainly not to use that data for drug approval, but for labelling or the designing of a new trial or... As you said, not to have collected data on the SAP would have been suspicious. In fact, it would be the noteworthy event. Beyond SAP however, I do feel tfcfox's frustrations. It was not cool to find out in the Zehr interview that a new ph III trial was conducted without telling the shareholders. REK justified this because, (to qoute her from the article), "we've been criticized by Health Canada in the past about releasing information about our studies." I don't buy this justification. I cannot imagine that announcing a study would earn the wrath of HC. Releasing information about the study would be a different story. As an aside, not the interchange of the terms ph III and study. You would have to read the article to see this. Jim, Fox, there is a way of justifying Rebecca's actions however. If you concede that her one overriding goal is to preserve DMX and its potential then she had to do what it took to maintain a share price that Aqua could sell into. No doubt it paints a picture of a Machiavellian CEO, but if thats what it takes then so be it. A junior biotech trying to go it alone will get help from no one.